Janux Therapeutics, Inc.
JANX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10,588 | $8,083 | $8,612 | $3,637 |
| % Growth | 31% | -6.1% | 136.8% | – |
| Cost of Goods Sold | $2,060 | $1,955 | $841 | $0 |
| Gross Profit | $8,528 | $6,128 | $7,771 | $3,637 |
| % Margin | 80.5% | 75.8% | 90.2% | 100% |
| R&D Expenses | $68,388 | $54,922 | $53,441 | $26,237 |
| G&A Expenses | $41,047 | $26,140 | $22,262 | $10,329 |
| SG&A Expenses | $41,047 | $26,140 | $22,262 | $10,329 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,060 | -$1,955 | -$841 | $0 |
| Operating Expenses | $107,375 | $79,107 | $74,862 | $36,566 |
| Operating Income | -$98,847 | -$72,979 | -$67,091 | -$32,929 |
| % Margin | -933.6% | -902.9% | -779% | -905.4% |
| Other Income/Exp. Net | $29,853 | $14,686 | $4,032 | $257 |
| Pre-Tax Income | -$68,994 | -$58,293 | -$63,059 | -$32,672 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$68,994 | -$58,293 | -$63,059 | -$32,672 |
| % Margin | -651.6% | -721.2% | -732.2% | -898.3% |
| EPS | -1.28 | -1.32 | -1.52 | -0.79 |
| % Growth | 3% | 13.2% | -92.4% | – |
| EPS Diluted | -1.28 | -1.32 | -1.52 | -0.79 |
| Weighted Avg Shares Out | 53,751 | 44,016 | 41,470 | 41,243 |
| Weighted Avg Shares Out Dil | 53,751 | 44,016 | 41,470 | 41,243 |
| Supplemental Information | – | – | – | – |
| Interest Income | $29,853 | $14,686 | $4,032 | $257 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,060 | $1,955 | $841 | $113 |
| EBITDA | -$96,787 | -$71,024 | -$66,250 | -$32,816 |
| % Margin | -914.1% | -878.7% | -769.3% | -902.3% |